| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
ATIC-IN-1 acetate targets ATIC dimerization, which is essential for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. By inhibiting dimerization, the compound disrupts ATIC function in the purine biosynthesis pathway. It has a Ki of 685 nM.
|
|---|---|
| ln Vitro |
In the presence or absence of 1 mg/mL and 10 mg/mL BSA, ATIC-IN-1 acetate (10 μM, 50 μM) is a selective inhibitor that displays a nonspecific aggregation mechanism [1]. The growth of MCF-7 cells is inhibited by ATIC-IN-1 acetate (100-500 μM; 48 h) [1]. Instead of increasing cell death, ATIC-IN-1 acetate (250 μM; 24-72 hours) resulted in reduced division [1].
In vitro, ATIC-IN-1 acetate (10 μM, 50 μM) is a specific inhibitor and shows nonspecific aggregate mechanism in the presence of 1 mg/mL and 10 mg/mL BSA. It inhibits the growth of MCF-7 cells at concentrations of 100-500 μM for 48 hours. Instead of increasing cell death, ATIC-IN-1 acetate (250 μM; 24-72 hours) results in reduced division. |
| ln Vivo |
Specific in vivo activity data for ATIC-IN-1 acetate are not detailed in available sources. As an inhibitor of purine biosynthesis with anticancer effects in vitro, it may have potential for in vivo studies in cancer models.
|
| Enzyme Assay |
Non-cellular enzyme assays for ATIC-IN-1 acetate involve measuring its ability to inhibit ATIC dimerization. The compound is incubated with purified ATIC protein, and the inhibition of dimerization is quantified using biophysical techniques such as size exclusion chromatography or surface plasmon resonance.
|
| Cell Assay |
In vitro cellular assays for ATIC-IN-1 acetate are performed using cancer cell lines such as MCF-7 breast cancer cells. Cells are treated with varying concentrations of the compound, and cell growth and division are assessed to evaluate its anticancer effects.
|
| Animal Protocol |
In vivo animal experiments for ATIC-IN-1 acetate would typically be conducted in mouse xenograft models using cancer cell lines sensitive to ATIC inhibition. The compound would be administered via appropriate routes, and tumor growth inhibition would be the primary endpoint.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for ATIC-IN-1 acetate are not detailed in available sources. As a small molecule inhibitor, its PK would be influenced by factors such as solubility, metabolic stability, and bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for ATIC-IN-1 acetate are not provided in available sources. As a research compound, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
ATIC-IN-1 acetate (compound 14) is a specific inhibitor of ATIC dimerization with a Ki of 685 nM. It exhibits anticancer effects by reducing cell numbers and division rates. It is supplied for research purposes only.
|
| Molecular Formula |
C23H37N7O7
|
|---|---|
| Molecular Weight |
523.58
|
| Related CAS # |
ATIC-IN-1;1402453-15-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~95.50 mM)
DMSO :~50 mg/mL (~95.50 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9099 mL | 9.5496 mL | 19.0993 mL | |
| 5 mM | 0.3820 mL | 1.9099 mL | 3.8199 mL | |
| 10 mM | 0.1910 mL | 0.9550 mL | 1.9099 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
